Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients

Theresa Hahn(Roswell Park Comprehensive Cancer Center), Philip L. McCarthy(Roswell Park Comprehensive Cancer Center), Meir Wetzler, Maria R. Baer(University of Maryland, Baltimore), V Jupudy(Buffalo State University), Allison N. Miller(Roswell Park Comprehensive Cancer Center), Arif Alam(Roswell Park Comprehensive Cancer Center), B K Mookerjee(Roswell Park Comprehensive Cancer Center), J Silva(Roswell Park Comprehensive Cancer Center), B Bambach(Women & Children's Hospital of Buffalo), M. S. Czuczman(Roswell Park Comprehensive Cancer Center), Aasma Shaukat(New York University), James L. Slack(Memorial Sloan Kettering Cancer Center), Asher Chanan‐Khan(WinnMed), Zale P. Bernstein(Hemophilia Center of Western Pennsylvania), Cherie Rondeau(Roswell Park Comprehensive Cancer Center)
Bone Marrow Transplantation
August 1, 2003
10.1038/sj.bmt.1704144
Cited by 79

Related Papers

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764